Tag: AFib

Adagio Medical Announces First Patient Enrollment in its iCLAS™ U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation

LAGUNA HILLS, Calif., Dec. 16, 2019 /PRNewswire/ — Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial.  The FDA approved study aims to evaluate the safety and efficacy of Adagio’s ultra-low temperature intelligent Continuous Lesion Ablation System […]

CardiaCare Awarded First Prize at the Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel Aviv, Israel

TEL AVIV, Israel, Dec. 16, 2019 /PRNewswire/ — CardiaCare, a startup developing wearable therapeutic devices for treating and monitoring AFib, announced today that it has been named the First Prize winner of the 2019 Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel […]

Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess™ For Recent Onset Atrial Fibrillation

NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ and the Toronto Stock Exchange (TSX) have halted trading of the Company’s common stock. […]

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals

PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation […]

Correvio Announces FDA Advisory Committee Meeting to Review Brinavess™ for Recent Onset Atrial Fibrillation

VANCOUVER, Nov. 4, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) will hold a Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting […]